⚠️ Teaching Case Note: This case has been de-identified and reconstructed for educational purposes. Clinical details reflect real surgical decision-making and outcomes. Patient identity is fully protected.
8.5 cm Liver Tumor With Portal Vein Invasion — Resected Laparoscopically, R0, No Transfusion
He was 54 years old, with a 10-year history of hepatitis B-related cirrhosis and no regular antiviral treatment. A routine health check found a liver mass. AFP came back above 1,210 ng/mL. One week later, he was sitting across from Dr. Qiang Xia's team at Ren Ji Hospital, Shanghai Jiao Tong University, with an 8.5 × 7.0 cm hepatocellular carcinoma in the right lobe — and tumor thrombus extending into the right portal vein branch and main trunk.
The conventional answer for this presentation is open surgery or liver transplantation. Dr. Xia's team chose a third path: total laparoscopic right hepatectomy with portal vein thrombectomy, ICG fluorescence navigation, and 3D volumetric planning — 210 minutes, 300 mL blood loss, no transfusion, discharge on day seven.
At 12 months, the patient was disease-free and back at work.
The Presentation: Cirrhosis, Massive Tumor, Portal Vein Thrombus
The patient's ECOG performance status was 0 — clinically well, no jaundice, no ascites. Liver palms were present; spider angiomata were absent. Child-Pugh Class A (6 points). ICG-R15 at 12% — within acceptable range for major hepatectomy, but at the upper boundary.
Enhanced CT and MRI defined the problem precisely. The right lobe mass measured 8.5 × 7.0 cm, with heterogeneous arterial enhancement and portal-phase washout — the hallmark imaging pattern of hepatocellular carcinoma. Tumor thrombus was visible as filling defects in the right portal vein branch and main trunk: PVTT Type II by the Cheng classification. The right hepatic vein was also involved.
The functional liver remnant (FLR) after right hepatectomy was estimated at 28% of standard liver volume — a borderline figure in a cirrhotic liver, where the threshold for safe resection is typically 40%. Three-dimensional reconstruction was used to simulate the resection plane, model residual volume, and map vascular anatomy before a single incision was made.
Tumor markers: AFP >1,210 ng/mL, PIVKA-II 800 mAU/mL. Staging: cT3N0M0, BCLC Stage B. No peritoneal seeding. No distant metastasis.
The MDT Decision: Why Laparoscopic, Why Now
The multidisciplinary team discussion centered on two questions: whether to operate at all, and whether to operate laparoscopically.
On the first question: the patient had no distant metastasis, preserved liver function, and an ECOG score of 0. The portal vein thrombus was Type II — involving the right branch and main trunk, but not completely occlusive. The oncological argument for resection was strong.
On the second question: Dr. Xia's team argued that the laparoscopic approach offered a specific advantage in this case. The magnified view of the laparoscope enables finer dissection of the hepatic hilum and portal structures than open surgery — particularly relevant when the operative field includes a tumor thrombus that must be extracted intact. ICG fluorescence navigation would allow real-time delineation of the resection plane and tumor margins, reducing the risk of positive margins in a complex anatomy.
A contingency plan was defined before the case began: if intraoperative assessment revealed inadequate FLR or severe fibrosis incompatible with safe resection, the team would convert to ALPPS (Associating Liver Partition and Portal vein ligation for Staged hepatectomy) or initiate living-donor liver transplantation (LDLT) preparation. The availability of a mature transplant program at Ren Ji Hospital made this contingency credible rather than theoretical.
The Operation: Laparoscopic Right Hepatectomy With Portal Vein Thrombectomy
Setup. General anesthesia, reverse Trendelenburg position, split-leg configuration. Five-port technique: camera port above the umbilicus, primary working port at the right lateral rectus border.
Exploration. Laparoscopic survey confirmed no peritoneal implants. The tumor occupied segments VI, VII, and VIII, with involvement of the right hepatic vein and right portal vein. No satellite nodules in the left lobe.
Hilar dissection — Glissonian approach. The right hepatic artery and right portal vein were dissected and temporarily occluded. The ischemic demarcation line appeared on the liver surface, confirming the anatomical boundary of the right lobe and validating the planned resection plane.
ICG fluorescence navigation. Intravenous ICG at 0.25 mg/kg was administered. Under near-infrared fluorescence imaging (Pinpoint/Firefly system), the tumor boundaries and intersegmental planes were visualized in real time. The fluorescence signal guided the transection line, ensuring maximal preservation of functional left lobe parenchyma while maintaining oncological margins.
Portal vein thrombectomy. After dividing the right hepatic ligaments and triangular ligament, the right portal vein wall was incised. The tumor thrombus was extracted in continuity — intact, without fragmentation. The portal vein main trunk was irrigated to confirm unobstructed flow before closure.
Hepatic vein division. The right hepatic vein was divided using an Endo-GIA stapler.
Parenchymal transection. CUSA (Cavitron Ultrasonic Surgical Aspirator) combined with bipolar electrocautery was used along the fluorescence-marked transection plane. Intrahepatic ductal and vascular structures were individually ligated. Pringle maneuver was applied intermittently — total inflow occlusion time 25 minutes.
Specimen extraction. The right lobe specimen was placed in a retrieval bag and extracted through a Pfannenstiel incision, eliminating the risk of port-site tumor seeding.
Operative data: Total time 210 minutes. Estimated blood loss 300 mL. No transfusion required.
Pathology and Recovery
Final pathology: Moderately differentiated hepatocellular carcinoma. Resection margins negative — R0. Portal vein tumor thrombus confirmed. No satellite nodules. Hepatic fibrosis Stage S4 (cirrhosis).
Recovery followed an Enhanced Recovery After Surgery (ERAS) protocol. The patient was mobilized on postoperative day one and the nasogastric tube was removed. Liquid diet resumed on day three. ALT and AST peaked and declined rapidly; total bilirubin remained normal throughout. Low-molecular-weight heparin was initiated for portal vein thrombosis prophylaxis. Entecavir/TAF was started for HBV suppression. No bile leak, no hemorrhage, no liver failure. Discharge on postoperative day seven.
Follow-Up: AFP Normalized, Liver Regenerated, Disease-Free at 12 Months
At one month: AFP had fallen to 15 ng/mL. Enhanced CT showed compensatory hypertrophy of the left lobe — FLR had increased from 28% to 45% of standard liver volume. The borderline remnant that had been the central preoperative concern had resolved through physiological regeneration.
At three months: adjuvant therapy was initiated — either preventive TACE (transarterial chemoembolization) or targeted immunotherapy (atezolizumab + bevacizumab), selected based on the multidisciplinary team's assessment of recurrence risk.
At 12 months: disease-free survival confirmed on imaging. The patient had returned to full-time work. Quality of life was self-reported as good.
Expert Commentary — Dr. Qiang Xia
"The conventional view is that portal vein tumor thrombus in hepatocellular carcinoma is a contraindication to minimally invasive surgery — that the complexity of thrombectomy and the risk of thrombus fragmentation require open access. This case challenges that view.
The laparoscopic approach offers a magnification advantage that is directly relevant to portal vein thrombectomy. The ability to visualize the thrombus extraction under high-definition magnification, with precise control of the portal vein wall, reduces the risk of fragmentation and tumor dissemination compared to the tactile-dominant environment of open surgery. ICG fluorescence navigation adds a second layer of precision — real-time confirmation of resection margins and intersegmental anatomy that cannot be replicated by palpation alone.
The functional liver remnant in this patient was 28% — below the threshold we would accept in a non-cirrhotic liver. The decision to proceed was based on Child-Pugh A status, ICG-R15 of 12%, and the 3D volumetric modeling that confirmed the left lobe anatomy was favorable. The ALPPS and LDLT contingencies were not theoretical — they were planned and available. That is what allows us to operate at the boundary of what is safe: not optimism, but preparation.
At 12 months, this patient is disease-free. His AFP is normal. His liver has regenerated. That is the outcome we planned for from the first MDT discussion. Precision surgery is not about the operation — it is about the entire pathway, from imaging to adjuvant therapy to long-term surveillance."
About Dr. Qiang Xia
Dr. Qiang Xia is a leading hepatobiliary surgeon at Ren Ji Hospital, affiliated with Shanghai Jiao Tong University School of Medicine. He specializes in liver transplantation and complex hepatic resection for primary and metastatic liver cancers. Dr. Xia is recognized for his expertise in minimally invasive liver surgery and living-donor transplant programs, and is widely regarded as one of China's foremost authorities on surgical management of advanced hepatocellular carcinoma.
How CMCS Supported This Patient
China Medical Concierge – Shanghai (CMCS) coordinated the full care pathway: specialist matching and priority access to Dr. Xia's team at Ren Ji Hospital, multidisciplinary team coordination across hepatobiliary surgery, interventional radiology, and oncology, Mandarin-English interpretation for all consultations — including the detailed informed consent process for a high-risk laparoscopic resection with portal vein thrombectomy — family communication support throughout the admission, and long-term follow-up coordination including AFP monitoring, enhanced CT scheduling, and adjuvant therapy planning.
For international patients and expatriates in Shanghai facing complex liver tumors — where the combination of surgical expertise, functional liver assessment, and post-operative oncological management determines long-term survival — CMCS provides end-to-end support from initial diagnosis to 12-month surveillance and beyond.
📧 contract@medicalsh.com | 📱 WhatsApp | 🌐 medicalsh.com
0 commenti